Abstract | OBJECTIVE: DATA SOURCES AND STUDY SELECTION: We performed a MEDLINE search of literature published from 1966 to 2000 for studies addressing the use of dopamine in the prevention and/or treatment of renal dysfunction. DATA EXTRACTION: Data were abstracted regarding design characteristics, population, intervention, and outcomes. Results of individual randomized clinical trials were pooled using a fixed effects model and a Mantel-Haenszel weighted chi-square analysis. DATA SYNTHESIS: We identified a total of 58 studies (n = 2149). Of these, outcome data were reported in 24 studies (n = 1019) and 17 of these were randomized clinical trials (n = 854). Dopamine did not prevent mortality, (relative risk, 0.90 [0.44-1.83]; p =.92), onset of acute renal failure (relative risk, 0.81 [0.55-1.19]; p =.34), or need for dialysis, (relative risk, 0.83 [0.55-1.24]; p =.42). There was sufficient statistical power to exclude any large (>50%) effect of dopamine on the risk of acute renal failure or need for dialysis. CONCLUSIONS: The use of low-dose dopamine for the treatment or prevention of acute renal failure cannot be justified on the basis of available evidence and should be eliminated from routine clinical use.
|
Authors | J A Kellum, J M Decker |
Journal | Critical care medicine
(Crit Care Med)
Vol. 29
Issue 8
Pg. 1526-31
(Aug 2001)
ISSN: 0090-3493 [Print] United States |
PMID | 11505120
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Cardiotonic Agents
- Dopamine
|
Topics |
- Acute Kidney Injury
(drug therapy, mortality, therapy)
- Cardiotonic Agents
(therapeutic use)
- Dopamine
(therapeutic use)
- Humans
- Randomized Controlled Trials as Topic
- Renal Dialysis
- Treatment Outcome
|